» Articles » PMID: 28652564

Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program

Overview
Journal Ann Transplant
Specialty General Surgery
Date 2017 Jun 28
PMID 28652564
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND We identified risk factors for acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively) in recipients after hematopoietic stem cell transplantation (HSCT) from unrelated donors in the China Marrow Donor Program (CMDP). MATERIAL AND METHODS We analyzed follow-up clinical information from 1824 patients who underwent HSCT between 2001 and 2010. RESULTS The incidence of aGVHD and cGVHD after transplantation was 49.29% and 27.3%, respectively. aGVHD incidence decreased as HLA matching increased (p<0.001). Incidence of aGVHD and cGVHD was higher in 2 HLA-A locus donor/recipient groups (02: 01/02: 06 and 02: 01/02: 07; p≤0.022). aGVHD incidence was associated with patient age, absence of rabbit anti-thymocyte globulin (ATG) pretreatment, and disease status (p≤0.040). aGVHD appeared to be a risk factor for cGVHD, and total body irradiation (TBI) was also associated with cGVHD. Patients with cGVHD after transplantation had a higher survival rate than patients without cGVHD (p<0.001), which may be due to reduced relapse rates. Survival was also associated with ATG prophylaxis and disease status. CONCLUSIONS The incidence of GVHD after HSCT from unrelated donors in the Chinese population is similar to the results reported from other countries. A high degree of HLA matching, a conditioning regimen without TBI, and the use of ATG may reduce the incidence of aGVHD.

Citing Articles

[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(6):525-533.

PMID: 39134482 PMC: 11310805. DOI: 10.3760/cma.j.cn121090-20240608-00214.


Understanding and treatment of cutaneous graft-versus-host-disease.

Hong J, Fraebel J, Yang Y, Tkacyk E, Kitko C, Kim T Bone Marrow Transplant. 2023; 58(12):1298-1313.

PMID: 37730800 PMC: 11759061. DOI: 10.1038/s41409-023-02109-x.


Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Cao X, Li J, Lu P, Liu K Int J Hematol. 2022; 116(3):315-329.

PMID: 35737192 DOI: 10.1007/s12185-022-03398-6.


iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts.

Hess N, Bharadwaj N, Bobeck E, McDougal C, Ma S, Sauer J Life Sci Alliance. 2021; 4(7).

PMID: 34112724 PMC: 8200291. DOI: 10.26508/lsa.202000999.


[Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (Ⅲ) -acute graft-versus-host disease (2020)].

Zhonghua Xue Ye Xue Za Zhi. 2020; 41(7):529-536.

PMID: 32549120 PMC: 7449769. DOI: 10.3760/cma.j.issn.0253-2727.2020.07.001.


References
1.
Eapen M, ODonnell P, Brunstein C, Wu J, Barowski K, Mendizabal A . Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014; 20(10):1485-92. PMC: 4163123. DOI: 10.1016/j.bbmt.2014.05.015. View

2.
Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S, Noto S . The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant. 1997; 19(6):571-6. DOI: 10.1038/sj.bmt.1700708. View

3.
Grigg A, Gibson J, Bardy P, Reynolds J, Shuttleworth P, Koelmeyer R . A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant. 2007; 13(5):560-7. DOI: 10.1016/j.bbmt.2006.12.449. View

4.
Gale R, BORTIN M, van Bekkum D, BIGGS J, Dicke K, Gluckman E . Risk factors for acute graft-versus-host disease. Br J Haematol. 1987; 67(4):397-406. DOI: 10.1111/j.1365-2141.1987.tb06160.x. View

5.
Shlomchik W . Graft-versus-host disease. Nat Rev Immunol. 2007; 7(5):340-52. DOI: 10.1038/nri2000. View